Dianthus Therapeutics Inc. (DNTH) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (58/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-26.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Dianthus Therapeutics Inc. (DNTH) advanced +0.47% to $82.70 as options desks priced 58% call premium vs. 42% put protection around the $81 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (-26.0% (NI vs OCF)) as receivables rose.
Regeneron (REGN) delivered earnings and revenue surprises of +24.81% and +12.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
Dianthus Therapeutics has delivered very strong multi year gains, which naturally raises a question for anyone looking at the stock today. Is the current share price still in line with what the balance sheet and book val
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DNTH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DNTH. Explore sector supply chains on /butterfly.
Why DNTH Stock advanced +0.47% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (-26.0% (NI vs OCF)) as receivables rose.